Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

William Mark Richardson; Jill T Shah; Daniel R Mazori; Avrom S Caplan; Kristen I Lo Sicco; Alisa N Femia

doi:10.1001/jamadermatol.2024.0403

Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

JAMA Dermatol. 2024 Apr 17:e240403. doi: 10.1001/jamadermatol.2024.0403. Online ahead of print.

Authors

William Mark Richardson¹, Jill T Shah¹, Daniel R Mazori¹, Avrom S Caplan¹, Kristen I Lo Sicco¹, Alisa N Femia¹

Affiliation

¹ The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York.

PMID: 38630455
PMCID: PMC11024728 (available on 2025-04-17)
DOI: 10.1001/jamadermatol.2024.0403

No abstract available

Plain language summary

This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.